Background: The presence of antimicrobial allergy designations ('labels') often substantially reduces prescribing options for affected patients, but the frequency, accuracy and impacts of such labels are unknown.
Introduction
It is estimated that 10% -30% of patients are designated (or 'labelled') as having an allergy to one or more antimicrobials. 1 -3 Antimicrobial allergy labels (AALs) represent a heterogeneous group of adverse drug reactions (ADRs), both immune mediated (Type B) and non-immune mediated (Type A) in origin. 4, 5 Despite potential variations in pathogenesis, the clinician's approach to antimicrobial allergy recording and labelling is often the same. 1, 2, 6, 7 While small retrospective studies have suggested that any AAL may be associated with inferior patient outcomes, increased antimicrobial usage, longer antimicrobial duration and increased use of broad-spectrum antimicrobials, 2, 3, 8, 9 this has never been assessed in a large national cohort or considered as a component of antimicrobial stewardship initiatives.
The Australian National Antimicrobial Prescribing Survey (NAPS) collects data on inpatient antimicrobial prescribing from public and private hospitals throughout Australia. 10, 11 Using this database, we examined the national prevalence of AALs in Australian inpatients and explored the impact of all AALs on antibiotic usage and the appropriateness of prescribed antibiotics.
Methods
Data were obtained from the available NAPS database for Australian hospitals from all jurisdictions (August 2013 to December 2014). The NAPS is a standardized electronic auditing tool developed in 2013 to assist healthcare facilities monitor antimicrobial prescribing practices and facilitate local quality improvement. 11 Participation is voluntary and data are submitted through a web-based interface to a central database. 12 In 2014, Patient data are included in the NAPS if the patient was prescribed an antimicrobial between 08.00 h and the time of review on the audit day, had received a single dose in the previous 24 h or had received an antimicrobial for surgical prophylaxis in the previous 24 h. Outpatients, daystay and non-admitted emergency department patients were excluded. 12 The dataset includes the following: antimicrobial usage (agent, dose, frequency, route, duration); baseline demographics [age, gender, documented antimicrobial allergies, admitting specialty, hospital location, funding type (public/private), bed size]; infection history (infection site, infection type, documentation); compliance with the Australian Antibiotic Guidelines; and antimicrobial appropriateness score. 12, 13 As described previously, 12 assessments of antimicrobial appropriateness are undertaken by the staff responsible for antimicrobial stewardship (infectious diseases specialists, clinical microbiologists, other medical practitioners, pharmacists, nurses or infection control practitioners) according to a structured algorithm, and appropriateness is defined as follows: 1 (optimal); 2 (adequate); 3 (suboptimal); 4 (inadequate); or 5 (not assessable). 10, 12 The appropriateness algorithm was developed using an expert consensus approach and is based on a composite assessment of: (i) compliance with the national guideline 13 or locally endorsed guidelines; (ii) antimicrobial coverage of causative pathogens; (iii) use of narrow-spectrum antimicrobials where possible; (iv) dosage and/or route; (v) duration if the end date is documented; (vi) allergy mismatch or drug interaction; and (vii) surgical prophylaxis duration ,24 h. Patients with poor documentation or who are complex may be classified as non-assessable. A score of 1 or 2 is considered to be 'appropriate' and 3 or 4 as 'inappropriate'. We defined a 'restricted antibiotic' as a third-or fourth-generation cephalosporin, carbapenem, fluoroquinolone or glycopeptide antibiotic. These restricted antibiotics are targets of Australian antimicrobial stewardship programmes. In hospitals without on-site expertise, appropriateness was assessed by the NAPS team. Validation of local and remote assessors has demonstrated that there is agreement between antimicrobial assessment teams. 14 We divided patients into two groups based upon the presence or absence of an AAL or no AAL (NAAL). All AALs reported were included, and therefore could represent a non-immune (Type A) or immunemediated (Type B) ADR, according to previous definitions. 5 AAL descriptions were not available for further analysis. Baseline demographics, antimicrobial usage and antimicrobial appropriateness were compared between AAL and NAAL groups. Subgroup analysis was performed for immunocompromised hosts, defined as those admitted under haematology, oncology or stem cell or organ transplantation services.
Statistical analysis
Categorical variables were summarized and compared between groups using a x 2 test. Continuous variables were summarized and compared using Student's t-test or the Wilcoxon signed-rank test, as appropriate. A P value of ,0.05 (two-tailed) was deemed statistically significant. Statistical analyses were performed using Stata 13.0 (StataCorp, College Station, TX, USA).
Results

Baseline demographics and AAL prevalence
There were 33 421 antimicrobial prescriptions recorded in 21031 patients in the NAPS for the study period. When comparing the AAL and NAAL groups, AAL patients were older 71 (IQR 56 -82) versus 65 (IQR 44 -78) years, P, 0.0001] with a female predominance [2235/3787 (59%) versus 1514/3787 (39%), P, 0.0001] ( Table 1 ). An AAL was reported in 18% (3787/ 21 031) of patients, with no difference between public (18%; 505/2778) and private (18%; 3282/18 253) hospital patients, but some difference in AAL prevalence for hospital geographical location (18% major cities, 21% inner regional, 16% outer regional and 8% remote hospitals, P, 0.0001). Among various inpatient units, the highest AAL prevalence was noted in solid organ transplant (SOT; 25%) and respiratory (25%) units. The AAL prevalences for other identified units were as follows: 24% acute care; 23% infectious diseases; 22% nephrology; 20% general medicine; 19% cancer; 16% orthopaedic surgery; 14% general surgery; 12% obstetrics and gynaecology; 7% trauma and burns; and 3% paediatrics.
AAL descriptions
The most commonly reported AALs in the AAL group were: b-lactams ( 
Antibiotic usage
Antibiotic usage for antimicrobial class for AAL and NAAL patients is shown in Figure 1 . A higher proportion of AAL patients had more than one recorded non-compliant antimicrobial prescription compared with NAAL patients (21.3% versus 20.8%, P ¼0.0001). The median number of antibiotics prescribed per patient was also higher in AAL than in NAAL patients ( Antibacterial agents constituted 91% of antimicrobial prescriptions, with the proportion of antimicrobials prescribed for AAL and NAAL and shifts towards restricted antibiotic usage demonstrated in Figure 2 . The top 10 commonly prescribed antibiotics for both AAL and NAAL groups are shown in Table 2 . Ceftriaxone was the most frequently prescribed antibiotic in the AAL group. Not surprisingly, b-lactam antibiotics were prescribed less frequently in the AAL group versus the NAAL group (OR 0.47, 95% CI 0.43 -0.50, P , 0.0001). In the AAL group a higher number of patients were prescribed a fluoroquinolone (OR 2.07, 95% CI 1.83 -2.34, P , 0.0001), glycopeptide (OR Trubiano et al. 1 .59, 95% CI 1.38 -1.83, P, 0.0001), carbapenem (OR 1.74, 95% CI 1.43 -2.13, P , 0.0001) or cephalosporin (OR 1.13, 95% CI 1.06 -1.22, P ¼ 0.0004). AAL patients used a high proportion of restricted antibiotics compared with NAAL patients (OR 1.95, 95% CI 1.78 -2.15, P, 0.0001). Restricted antibiotic usage for patients in respect of reported antibiotic allergies is demonstrated in Figure 3 .
Antibiotic usage in immunocompromised hosts
Among immunocompromised patients, those with an AAL were prescribed more fluoroquinolones (OR 1.92, 95% CI 1.23 -3.02, P ¼ 0.005), glycopeptides (OR 1.79, 95% CI 1.17 -2.73, P ¼ 0.01) and carbapenems (OR 2.35, 95% CI 1.50 -3.68, P ¼ 0.0003) than NAAL patients. In haematology/oncology patients, 
Antimicrobial appropriateness
The rates of inappropriate antimicrobial prescribing for AAL and NAAL patients are shown in Table 3 
Discussion
Based on this large national survey, approximately 1 in 5 patients (18%) have an AAL-a considerable clinical burden considering the inferior outcomes associated with such a designation. 1, 3, 8, 9 In particular, we noted that patients designated with an AAL were associated with high rates of inappropriate antimicrobial use. This is especially concerning for immunocompromised patients, given the potentially serious implications of any infections and the enhanced risk of colonization with multi-resistant pathogens. 8 Previous authors have highlighted the fact that many reported antibiotic 'allergies' are in fact drug intolerance (Type A), or distant unknown reactions unlikely to be replicated on skin-prick testing or oral challenge. 2, 15 Among patients with reported antimicrobial allergy (primarily to b-lactams), only 10% -20% are positive on formal testing. 16, 17 Given this and the potential consequences of an incorrect AAL, accurate assessment for true antibiotic allergy could now be considered a potentially important antibiotic stewardship issue, with the aim of undertaking antimicrobial allergy de-labelling where appropriate.
AAL prevalence varied greatly between admitting units, being highest in SOT and respiratory patients (25%) and (perhaps not surprisingly) lowest in paediatric patients (3%). In a retrospective Trubiano et al.
cohort of general surgical and medical patients AAL prevalence was estimated to be 11%, while in a group of cancer patients it was 23%. 3, 9 The units with the highest prevalence are potentially key targets for antimicrobial allergy de-labelling programmes. The rate of antimicrobial allergy captured via NAPS reflects the real-world reporting of allergy labels, since it includes both Type Impacts of antimicrobial allergy B ADRs (immune mediated, on target effects) and Type A ADRs (non-immune-mediated, off-target effects). 18 Moskow et al.
7
demonstrated that 36% of electronic allergy records lacked an allergy description, preventing prescribers from being able discern between true allergies and drug side effects. We have previously estimated from a single-centre NAPS experience that almost 25% of antibiotic 'allergies' are likely Type A and another 25% unknown. 15 Therefore, we postulate that a large portion of our antibiotic allergy labels would be unsubstantiated in medical records and of non-immune origin, leaving scope for greater allergy documentation and de-labelling to improve the quality of prescribing.
Utilizing the NAPS structured appropriateness scale we demonstrated that inappropriate prescribing was higher in patients with an AAL. More pronounced was the difference in appropriateness amongst the highest users of antimicrobials-patients with haematological malignancy or cancer. Potentially, the removal of antimicrobial labels in these groups may aid appropriateness measures. It was not surprising that in patients with a b-lactam AAL there was a significant reduction in the utilization of all b-lactams. When further examining the AAL group there was a notably higher proportion of fluoroquinolones, glycopeptides, cephalosporins and lincosamides used.
This study has some limitations. Firstly, by examining only inpatient AALs we were unable to accurately differentiate between Type A and B ADRs. While a standardized protocol (an internally validated tool for assessing antibiotic appropriateness) is provided to participating NAPS hospitals, variation in clinician interpretation is expected. While most hospitals performed hospital-wide surveys, targeted units may have been surveyed at some centres. We defined a restricted antibiotic based upon Australian antimicrobial stewardship targets, which may differ from those used in other centres. Furthermore, an assessment of restricted antibiotic use in immunocompromised hosts is confounded by the empirical use of broad-spectrum antibiotics as first-line therapy for febrile neutropenia (e.g. cefepime, piperacillin/tazobactam). There is the potential for ascertainment bias, as the more antimicrobials patients receive, the greater may be the likelihood of obtaining an AAL. Nonetheless, this multi-site prospective NAPS study does provide a valuable estimate of the national AAL burden and its impact on antimicrobial prescribing patterns.
Given our findings, we believe antibiotic allergy clinics and de-labelling programmes, which have been shown to be highly successful in accurately and safely removing allergy labels, should be considered as an important component of national Trubiano et al.
stewardship initiatives. 16 Models have been proposed of the integration of antibiotic allergy services into stewardship programmes to improve antibiotic utilization. 2, 19, 20 A small number of pilot studies have demonstrated an increase in b-lactam uptake and reduced antimicrobial costs with inpatient penicillin skin-prick testing, 21, 22 while pharmacy referral to skin-prick testing and physician education programmes have also improved b-lactam usage. 23, 24 A solution to AALs may lie in coordinated approaches, incorporating inpatient and outpatient allergy testing and improving electronic allergy recording, antimicrobial stewardship allergy identification and both infectious disease and allergy physician engagement. 7, 25 Antibiotic allergy should remain a priority issue for infectious diseases physicians, who are often required to consult and manage patients with complex antimicrobial allergy histories.
Conclusions
In an era of increasing antimicrobial resistance and a diminishing antibiotic pipeline the appropriate use of antibiotics has never been more important. We demonstrate that AALs remain highly prevalent in Australian inpatients and are associated with Impacts of antimicrobial allergy JAC inappropriate and excess antimicrobial prescribing. This supports the consideration of targeted antimicrobial stewardship initiatives involving antibiotic allergy de-labelling programmes.
